CV Sciences Files 8-K on Financials

TL;DR

CV Sciences dropped an 8-K on financials as of March 27, 2025. Check it out.

AI Summary

CV Sciences, Inc. filed an 8-K on August 13, 2025, reporting on its Results of Operations and Financial Condition as of March 27, 2025. The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits. The company was formerly known as CannaVEST Corp. and Foreclosure Solutions, Inc.

Why It Matters

This 8-K filing provides investors with updated financial information and disclosures for CV Sciences, Inc., which is crucial for understanding the company's current operational status and financial health.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of financial information and does not appear to contain any significant new risks or adverse events.

Key Players & Entities

• CV Sciences, Inc. (company) — Registrant
• CannaVEST Corp. (company) — Former company name
• Foreclosure Solutions, Inc. (company) — Former company name
• August 13, 2025 (date) — Filing date
• March 27, 2025 (date) — Period of report

FAQ

Filing Documents

• cvsi-20250813.htm (8-K) — 51KB
• cvsi-ex99_1.htm (EX-99.1) — 577KB
• 0000950170-25-107984.txt ( ) — 745KB
• cvsi-20250813.xsd (EX-101.SCH) — 22KB
• cvsi-20250813_htm.xml (XML) — 4KB

02 Results of Operations and Financial Conditions

Item 2.02 Results of Operations and Financial Conditions The information provided below in "Item 7.01 - Regulation FD Disclosure" of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure On August 13, 2025, CV Sciences, Inc. (the "Company") issued a press release regarding the Company's financial results for its quarter ended June 30, 2025. A copy of that press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference. The press release includes non-GAAP financial measures as defined in Regulation G. The press release also includes a presentation of the most directly comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the United States (GAAP), information reconciling the non-GAAP financial measures to the GAAP financial measures and a discussion of the reasons why the Company's management believes that presentation of the non-GAAP financial measures provides useful information to investors regarding the Company's financial condition and results of operations. The non-GAAP financial measures presented therein should be considered in addition to, not as a substitute for, or superior to, financial measures calculated and presented in accordance with GAAP. Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements. The information set forth under Item 7.01 of this Current Report on Form 8-K ("Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference in

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit Number Description 99.1 Press Release of CV Sciences, Inc. dated August 13, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * Filed herewith. 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CV SCIENCES, INC. Date: August 13, 2025 By: /s/ Joseph Dowling Joseph Dowling Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR